NCT06974786
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06974786
Title Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)
Acronym FASTER
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham RECRUITING Birmingham Alabama 35294 United States Details
Colorado Blood Cancer Institute RECRUITING Denver Colorado 80218 United States Details
Oncology Hematology Care RECRUITING Cincinnati Ohio 45242 United States Details
SCRI Oncology Partners RECRUITING Nashville Tennessee 37203 United States Details
Virginia Oncology Associates RECRUITING Norfolk Virginia 23502 United States Details
University of Wisconsin Clinical Science Center RECRUITING Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field